Thus, these observations show the potential of CD19-CAR-iNKT cells to eliminate CD19+ malignancies through their CAR, while promoting immunoregulation and tumor control through the engagement of the TCR:CD1d machinery. This evidence concerns the gene CD1D and neoplasm.